ChosenMed of Beijing Completes B Round for Oncology Precision Medicine
Apr 22, 2020
publication date: Apr 22, 2020
ChosenMed Technology, a Beijing oncology precision medicine company, raised "hundreds of millions of yuan" in a Series B round led by Shanghai Lianhe Investment. The company offers products for early screening, prevention and diagnosis of tumors, dynamic monitoring, medication guidance, prognosis evaluation and bioinformatics data analysis. The company claims to have a complete industrial chain for its business, from upstream production of instruments and reagents, to mid-stream third-party oncology medical detection labs, and downstream genetic analysis and medical advice for patients. More details....
Share this with colleagues:
Sorry this page is available to subscribers only. If you're not a subscriber why not subscribe today? If you are already a subscriber, please login. If you believe you should have received this message in error, please contact us .